Project Grant R43AI092923

This Project Grant award, totaling $390,942.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The goal of the project is to use self-assembled protein nanocages (SAPNs) as a universal flu vaccine platform to enhance the effectiveness of influenza vaccines. Specifically, the SAPNs will present multiple copies of three highly conserved influenza antigens: trimeric...

This $649,896 federal Project Grant awarded by the U.S. Department of Agriculture's (USDA) National Institute of Food and Agriculture (NIFA) under the Agriculture and Food Research Initiative (AFRI) program supports the development and testing of an mRNA vaccine cocktail against influenza A viruses (IAV) in livestock. The project aims to create a universal influenza vaccine that can provide broad protection against diverse IAV strains, including highly pathogenic avian influenza (HPAI) H5N1...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a broad-spectrum influenza vaccine. The project aims to evaluate recently discovered neuraminidase broadly neutralizing antibodies (NA BNAbs) and engineer NA immunogens that can engage diverse BNAb precursors, a strategy called germline targeting. This protein engineering effort...

The Defense Health Agency awarded Flugen Inc. a $6,237,445 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to optimize downstream recovery and stabilization of the drug substance for their intranasal influenza vaccine. The three-year grant also supports research on concurrent administration of Flugen's H3N2 M2SR monovalent influenza vaccine with inactivated flu vaccines in older adult populations. This award builds on Flugen's previous federal grants...

The University of Missouri System, under a $650,000 project grant from the USDA National Institute of Food and Agriculture (NIFA) Agriculture and Food Research Initiative (AFRI) program, is developing safe and effective live attenuated swine influenza vaccines using Newcastle disease virus (NDV) as the vector. The project aims to address the challenges with current swine influenza vaccines, which often fail to provide cross-protection against diverse virus strains. The key products and...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,968 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Viva Viral Vaccines, Inc. to develop a broad-spectrum, multivalent vaccine platform for pandemic and seasonal influenza. The platform leverages innovations in the production of influenza neuraminidase (NA) proteins in mammalian cells, enabling the development of VLP-based vaccines that can provide broad heterologous...

This Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000.00 in funding to Immuno Nano Med, Inc. to demonstrate the feasibility of producing a novel room-temperature-stable, dry-powder inhalable influenza vaccine. The goal is to develop an innovative, next-generation influenza vaccine technology that can promote public health by eliminating the pain points of current flu vaccines, such as the need...

This NSF Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award to Invvax, Inc. provides $996,606.00 in funding from July 1, 2025 to June 30, 2027 to develop stable prophylactic antibodies (SPABs) as long-term preventative treatments for infectious diseases. The project aims to discover antibody mutations that significantly enhance stability, extending their lifespan from weeks to years. The initial focus is on influenza, with the goal of creating SPABs that could...

This federal Project Grant award of $454,278.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop an adjuvanted intranasal influenza vaccine capable of generating lung-resident memory T cells to provide broadly cross-reactive and heterosubtypic immunity. The research project, conducted by the University of Kentucky Research Foundation, aims to characterize the T...

This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $256,000 will develop Recombinant BCG as a novel immunoadjuvant for viral infections. The awardee, Oncosting LLC located in Baltimore, Maryland, will optimize media and lyophilization manufacturing of BCG-STING, evaluate its immunological effects as an adjuvant for H1N1 influenza vaccination, and assess its protective effects as an H1N1 vaccine adjuvant. By adding stimulator of...